BioSpace News Archive

Vedanta Biosciences, announced a $16.6 million Series C-2 financing round, bringing the total capital raised in its Series C and C-2 round to $62.1 million.

The world’s leading online healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited announced on 23 September that the number of registered users on Ping An Good Doctor exceeded 300 million, implying that one in every three Chinese Internet users is a user of Ping An Good Doctor.

To demonstrate that treatment with the Revivent TC™ System is more effective than Guideline Directed Medical Therapy (GDMT) for the treatment of ischemic heart failure

Wharton Research Data Services is pleased to announce two first-of-their-kind global programs — the WRDS Advanced Research Scholar Program and Wharton Research Data Analytics Librarian Conference, held August 19-23 at the Penn Wharton China Center in Beijing.

American Specialty Health Ranks No. 4958 on the 2019 Inc. 5000 List with Three-Year Revenue Growth of 53%

Clovis Oncology, Inc. has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.

CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company announced the European Medicines Agency has granted PRIority MEdicines eligibility to its investigational CAR-T cell therapy fully human anti-BCMA autologous chimeric antigen receptor T Cells for the treatment of relapsed or refractory multiple myeloma.

Insulet Corporation announced it has received clearance from the U.S. Food and Drug Administration for an Alternate Controller Enabled Infusion Pump.

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced positive top-line results from its pivotal Phase 3 clinical trial of its investigational StrataGraft® regenerative tissue.

I-Mab Biopharma announced that it has entered into a clinical research collaboration agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of I-Mab’s TJC4 and MSD’s anti-PD-1 therapy, KEYTRUDA® in patients with multiple cancer types.